Centre Hospitalier Universitaire de Besançon-ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2014

  1. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial

    The Lancet Oncology, Vol. 15, Núm. 11, pp. 1269-1278

2013

  1. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

    British Journal of Cancer, Vol. 108, Núm. 5, pp. 1052-1060